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ABSTRACT
Vaccine trials, the most informative way of determining the efficacy of a vaccine, can also provide
valuable information about the burden of disease. The burden of Haemophilus influenzae type b (Hib)
remains a major barrier to the use of Hib vaccines, especially in Asia. Recent studies in Indonesia and
Bangladesh have used vaccine-trial designs, with known effective vaccines, to estimate the vaccine-
preventable burden of Hib disease in those communities. New vaccines against pneumonia and diar-
rhoeal diseases are usually directed at only one of various causes of the syndrome. In the case of pneu-
monia, it is very difficult to determine the aetiology in most cases, so the vaccine trial offers a means
of determining the burden of vaccine-preventable diseases. This is particularly important for pneumo-
coccal vaccines as serotype replacement may reduce the effectiveness of the vaccines in the field. This
approach would underestimate disease burden if vaccines were found to have an impact on syndromes
other than those against which they are directed, and might lead to errors in estimation if there were
erroneous assumptions about the efficacy of the vaccine against the condition under investigation.
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INTRODUCTION
Vaccination has been used for the prevention of specific
conditions in different parts of the world for centuries,
but the 20th century saw the development of vaccina-
tion as a highly effective global public-health strategy
(1). The proof that a vaccine is effective has tradition-
ally been provided by a vaccine trial, using epidemio-
logical methods that have been developed over the
course of the 20th century. Towards the end of the cen-
tury, there was a dramatic increase in the price of vac-
cines, largely because their development and produc-
tion has been taken over by a small number of large
pharmaceutical companies (2). Thus, the later years of
the century saw the price of vaccine rise from a few
cents to over US$ 50 per dose. This development has
meant that even rich countries must now weigh care-
fully the costs against the benefits of vaccination. The
benefits can be seen as having two components__the bur-
den of the disease that is to be prevented and the effec-
tiveness of the vaccine. These two factors together com-
prise the vaccine-preventable burden of disease. 
This paper discusses the growing use of vaccine trials
as a method of measuring the burden of disease, the
relevance of burden of vaccine-preventable disease as
a concept, and the often unrecognized shortcomings of
this approach.
In its simplest form, a vaccine trial can be seen as
the introduction of a vaccine leading to the reduction
or disappearance of the disease against which the vac-
cine is directed. In the case of an inexpensive and
effective vaccine directed against a common disease,
such as measles, this may be sufficient to prove the
value of the vaccine to public-health officials and to
the general public. However, with vaccines that may
not be highly efficacious, or diseases that vary in their
intensity from year to year, this approach is inclined to
yield misleading results. For example, in sub-Saharan 
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Africa and the Middle East, after decades of use
against regular epidemics, there are still doubts about
the efficacy and duration of protection of meningococcal
AC polysaccharide vaccines in young children (3).
Another approach is to introduce a vaccine in a man-
ner that leads to only part of the population being vac-
cinated and then to use epidemiological techniques to
compare the likelihood of disease in vaccinated indi-
viduals to that in unvaccinated ones. The most com-
monly-used methods include case-control studies in
which the rate of vaccination is compared in diseased
versus non-diseased individuals  and large-scale model-
ling techniques in which patterns of disease are related
to patterns of vaccine usage (4). The problem with
these open approaches is that confounding factors are
likely to influence the likelihood of an individual
receiving the vaccine, making direct comparisons
potentially biased. Such biases are accentuated where
the receipt of a vaccine is based on individual choice.
All such methods are inferior to the traditional double-
blind, randomized, controlled trial (5). In such a trial,
the population under study is effectively divided into
compared groups who are equal in every respect,
including the likelihood that a case of the disease in
question will be detected. In most large trials, this
approach avoids the issue of bias, as it can be truly said
that the only difference between the groups is whether
or not they received the vaccine. Thus, any observed
difference in rates of disease, patterns of disease, or
mortality can be assumed to be due to the vaccine. If
the randomization is undertaken in a 1:1 ratio, it can be
assumed that the number of cases in the control group
is an indication of the number that would have been
found in the vaccinated group in the absence of a vac-
cine. The number of cases that were prevented by the
vaccine can then be calculated, and this presented as a
proportion of the total number of cases that would have
been expected in the absence of a vaccine.  This repre-
sents a measure of the efficacy of the vaccine. It is
important to note that these calculations do not require
that all such cases in the population are detected, just
that the methods used for their detection are identical
in the two groups. For example, if a trial is conducted
for a vaccine to prevent  pneumonia, but only half the
cases of pneumonia that occur in the study population
are detected, the estimate of vaccine efficacy should be
the same, although the number of cases upon which
that estimate is based will be only half and, therefore,
the 95% confidence interval surrounding the estimate
of efficacy will be correspondingly wider.
In some cases, vaccine trials are conducted that rely on
the use of tests for the detection of endpoint cases that
are less than 100% sensitive, less than 100% specific,
or both. The impact of these deficiencies will depend
on the incidence of the disease outcome in the commu-
nity under study. For example, the use of a test that is
less than 100% sensitive will have a similar impact on
the failure to detect a random proportion of cases, pro-
vided the test does not perform differently in vaccinat-
ed and unvaccinated individuals. The total number of
cases detected will be reduced, but the estimate of the
proportion that is prevented and, therefore, the esti-
mate of vaccine efficacy should be similar.  The cost of
the study will be seen in terms of the precision of the
estimate and the width of the confidence interval, and
will be greater if the endpoint under study is of low
incidence. In the pneumococcal field, a number of
assays have been proposed for use as endpoints in vac-
cine trials. Culture-positive pneumococcal disease is
highly specific, but as most cases of pneumococcal
pneumonia are blood culture-negative, it is very insen-
sitive. In the recent South African trial, in which
39,836 infants were randomized to receive a pneumo-
coccal vaccine or placebo, only 20 cases of proven
invasive pneumococcal disease of vaccine serotypes
were detected (6). The point estimate of vaccine effica-
cy (83%) was consistent with previous trials of similar
vaccines, but because of the small numbers the confi-
dence intervals were wide (Table 1).
Table 1. Vaccine efficacy of 9-valent Pnc-CRM
pneumococcal conjugate vaccine in HIV-
negative South African infants (6)
Percentage
of vaccine
Outcome      Vaccinees  Controls  efficacy 
(95% CI)
Radiological pneumonia 169 212 20 (2,35)
All invasive Pnc disease 11 19 42 (28,75)
Invasive Pnc disease-
vaccine serotypes 3 17 83 (39,97)
CI=Confidence interval
The use of a test with poor specificity has more severe
consequences on a vaccine trial, particularly where the
incidence of the endpoint condition is low.  Depending
on the specificity of the test and how widely it is
applied in the study population, a number of false-posi-
tive cases will be detected that will be found equally in
both vaccinated and unvaccinated individuals, greatly
reducing the measured impact of the vaccine and, 
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therefore, the estimated efficacy. For example, in the
South African pneumococcal vaccine trial, the exact
number of respiratory infections investigated among
trial participants to produce 20 endpoint cases is not
stated, but it is likely to be over 2,000. Had an indirect
test of pneumococcal disease, such as a pneumolysin
immune complex assay (7), been used, it may have a
specificity of 95% which seems reasonable. However,
such a specificity would add 50 cases to each group,
virtually invalidating any measurement of efficacy.
The impact of this effect would be less if the test is
applied selectively. It must be recognized that this is
different from the situation where a vaccine is being
used for preventing a specific clinical endpoint, such
as radiological pneumonia, where the organism targeted
by the vaccine is only responsible for a fraction of
those endpoints (Table 1). This will affect the potential
efficacy of the vaccine against that endpoint, yet the
measures used to identify the endpoint cases could still
be regarded as quite specific. The (usually unknown)
fraction of radiological pneumonia that is potentially
vaccine-preventable represents an upper limit to the
potential efficacy of a vaccine directed against that
endpoint.
Measurement of burden of disease 
In vaccinology, disease-burden studies are needed to
determine the potential value of a vaccine and, there-
fore, the need for a government to introduce it.  Where
a vaccine is inexpensive and safe, it may simply be
sufficient to know that the disease exists with suffi-
cient frequency in the community to justify the effort
and extra costs involved in its introduction. Thus, in
the case of polio, the World Health Organization
(WHO) coordinated a large number of 'lameness sur-
veys' to demonstrate the importance of polio at country
level to convince governments to include the vaccine
in their programmes (8). These were simple, inexpen-
sive studies, but a large number was needed to over-
come perceptions that polio was not a condition of
great public-health significance in developing countries.
The specific clinical picture presented by polio made
the estimation of disease burden simple. Indeed, sur-
veillance for the clinical syndrome of "acute flaccid
paralysis" has formed the benchmark for the success of
the current global polio-eradication campaign.
In the case of vaccines directed against causes of
diarrhoea and pneumonia, the disease-burden question
is much more complicated and contains a number of
conceptual layers. The first level is the overall burden
of diarrhoea or pneumonia. In both the cases, the bur-
den covers the spectrum of the syndrome, ranging
from the very common, mild forms to the less com-
mon, life-threatening forms, and finally to the burden
of mortality attributable to the syndrome. The second
level to consider is then the proportion of cases that are
caused by the organism against which the vaccine is
directed, and this may differ through the spectrum of
severity of the syndrome. For example, pneumococcus
may cause a small proportion of mild-pneumonia
cases, but a larger proportion of severe cases (9).
Rotavirus, on the other hand, causes a similar propor-
tion of mild and severe cases of diarrhoea (10). The
contribution of these organisms to the mortality burden
of pneumonia and diarrhoea remains unknown and
may be larger than that inferred from studies focused
on severe disease. The third level to consider relates to
the strains or serotypes of the organism that cause disease.
These may vary in time or space, with the disease mani-
festation concerned, the severity of the disease, and the
age of the individual (11). Cross-protection between
strains or serotypes occurs, but this is usually less than
the protection offered against the strain or serotype
against which the vaccine is directed (12). To further
complicate the issue, vaccines directed against the bac-
terial causes of pneumonia also offer protection against
other disease manifestations caused by the same orga-
nisms, such as otitis media and meningitis. The level of
protection against these other manifestations is also
variable and may vary with serotypes (13).
Thus, for vaccines against the causes of pneumonia
and diarrhoeal disease, the notion of burden of disease
is multifaceted and complex. This is unfortunate as it
is these vaccines that are now becoming available at
high prices, calling for detailed cost-benefit analyses to
guide their introduction. To facilitate this, prospective
studies are being undertaken in a bid to provide a com-
posite picture of burden of disease, yet the more com-
plex these analyses become, the more inaccurate the
results will be. For example, otitis media is an impor-
tant component of burden of pneumococcal disease in
some settings, yet there are few studies of the burden
of otitis media from the developing world, and none
that describes burden in relation to aetiology.
It is becoming evident that the most meaningful
measure of burden of disease is the burden of vaccine-
preventable diseases, and this can only really be mea-
sured in the context of a vaccine trial. Furthermore, the
trial should be designed with burden of disease in
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mind, with as close as possible to complete detection
of each disease manifestation to be measured within a
known population (14). The size of the population
required could be smaller for the more common mani-
festations, introducing more intense sub-studies into
vaccine trials. Where possible, diagnostic tests can be
adjusted to maximize sensitivity for the purposes of
disease-burden estimates, recognizing that the associ-
ated loss of specificity may adversely affect the power
of the analysis to determine the efficacy of the vaccine.
As a general rule, specificity is more important when
trying to determine vaccine efficacy, while sensitivity
is more important when trying to assess the burden of
disease. Thus, while the South African trial provides
valuable information on the efficacy of the vaccine
against key endpoints, it provides no information on
the burden of preventable disease that did not fall into
its strict blood culture or radiological criteria. To
achieve this, it should have included a nested study in
which all cases of more common but less severe mani-
festations of pneumococcal disease (otitis media and
febrile bacteraemia), and all episodes of acute respira-
tory infection, as defined by WHO (cough or difficult
breathing + fast breathing) were identified. The fea-
tures of a vaccine trial that enable the estimation of
burden of disease are listed in Table 2.  
Vaccine trials provide information on the burden of
disease by providing a measurable 'vaccine effect',
usually the difference in incidence of a syndrome or
condition between vaccinated and unvaccinated
groups. It is assumed that this difference is due to the
effect of the vaccine and that the only effect of the vac-
cine is to prevent or modify infection due to the orga-
nism against which the vaccine is directed. If all the
cases occurring in the population are detected, this
observed difference translates directly into burden of
vaccine-preventable disease. Even if this is not the
case, a trial can provide important disease-burden
information by showing the proportion of the syn-
drome being studied that appears to be due to the
organism in question. An important assumption in
these exercises is the efficacy of the vaccine. If the
vaccine efficacy is 100%, the burden of vaccine-pre-
ventable diseases will be the true disease burden. If it
is less than 100%, the true disease burden will be
underestimated accordingly. If the vaccine has an
effect on rates of disease other than the infection
against which the vaccine is directed, resulting disease-
burden estimates will be very difficult to interpret.
Where herd immunity is likely to be a factor, cluster 
randomization is preferred over individual randomiza-
tion as it provides maximum vaccine effect (individual
protection plus herd immunity) and reduces the possi-
bility that herd immunity will reduce the measured effect
by providing some protection for the control group.
Table 2. Elements of a vaccine trial required for
estimation of burden of vaccine-preventable
diseases from the trial
A vaccine of known efficacy (or whose efficacy
will be known at the end of the trial)
A valid trial design (usually cluster-randomized or
individually-randomized design)
Ascertainment of all disease manifestations that
may be prevented by the vaccine
For each disease manifestation, complete ascertain-
ment of cases within a defined population.  (This
may be a sub-population of the trial population for
more common events)
Use of a critical trial endpoint that can be transport-
ed into other disease-burden studies or used for
monitoring the effectiveness of the vaccine post-
introduction
Collection of data that will allow the cost of each
recorded manifestation of disease to be estimated to
form the basis of an economic evaluation (desir-
able, not essential)
A number of vaccines have been developed against the
major causes of child death. While it has been fairly
straightforward to demonstrate that the disease in
question is an important cause of child death and that
the vaccine prevents the disease in question, it does not
necessarily follow that vaccination will prevent the
expected proportion of child deaths. There are two
important reasons for doubting this important connec-
tion. First, the immunological requirements to prevent
a death from, say malaria, may be quite different from
those required to prevent illness, as fulminating and
fatal disease appears to have a different pathogenesis
to milder forms of the disease (15). Second, very little
is known about the distribution of deaths from diar-
rhoeal disease and pneumonia within communities. To
prevent such deaths, it will be necessary to introduce
the vaccine in such a way that it reaches those children
who currently lack the most basic primary healthcare,
as this level of care is all that is required to prevent
most deaths due to pneumonia and diarrhoea. Thus,
prediction of vaccine-preventable mortality may be the
most elusive, yet the most important element of burden 
of disease. In the following sections, examples will be
presented which demonstrate the linkage between vac-
cine trials and disease-burden estimates.  
Vaccine studies that have contributed to disease-
burden information
Neonatal tetanus
Neonatal tetanus has long been recognized as an
important neonatal problem in developing countries,
usually attributed to poor management of the umbilical
cord during the neonatal period (16). Throughout the
developing world, neonatal deaths have been poorly
recorded, as most occur at home without birth registra-
tion. The idea that neonatal tetanus could be prevented
by maternal immunization provoked WHO to embark
on a series of studies of neonatal mortality to deter-
mine the burden of neonatal tetanus. Such studies were
possible because, unlike most other causes of neonatal
death, the clinical features of neonatal tetanus are charac-
teristic and dramatic, and so the diagnosis can be made
with reasonable accuracy using post-mortem question-
naire. However, it was a large, randomized trial of mater-
nal tetanus immunization undertaken in Bangladesh
that confirmed the true burden of that condition (17).
In that trial, which was designed to evaluate a cholera
vaccine, the controls who received tetanus vaccine and
who were later found to have been pregnant at the time
of immunization, had a 26% lower neonatal mortality
rate, with all the reduction evident in the 4-14-day
period (18). This trial provided convincing evidence of
both burden of neonatal tetanus and potential impact of
maternal tetanus immunization. It also opened the way
for future studies of the burden of neonatal tetanus
based on 4-14-day mortality rates.
Haemophilus influenzae type b
It is now 14 years since the highly effective Haemophilus
influenzae type b (Hib) conjugate vaccines were first
licensed for use in infants (19). During the early years,
their use was restricted to a few rich countries due to the
high prices charged for the vaccine. Now, with more pro-
ducers in the market, prices have fallen to $ 2-3 per dose.
This is still prohibitive for many countries, but the
Global Alliance for Vaccines and Immunization (GAVI)
has now provided funds for the poorest countries to
introduce Hib vaccines, provided the burden of disease
can be established. Now looming as the main obstacle to
the introduction of Hib vaccines in the developing world
is lack of understanding of the burden of disease. This is 
particularly evident in Asia and is the main reason
why, up to the present time, only one Asian country has
introduced Hib vaccine as part of its national immu-
nization programme.
Although Hib can cause a wide range of clinical
manifestations, most are very rare, and so for practical
purposes in developing countries, the burden of disease
must be considered as comprising meningitis and
pneumonia. Meningitis is an uncommon condition, but
the outcome is poor in terms of mortality (20-50% in
developing countries) and long-term sequelae (around
30% of survivors in most studies) (20). Pneumonia, on
the other hand, is very common, but only a fraction of
cases are due to Hib and at an individual level it is very
difficult to determine the aetiological agent responsible
for a case of pneumonia. To identify a case of Hib
pneumonia with certainty, it is necessary to identify the
Hib organism from blood culture, or from culture of
lung aspirate or pleural fluid. Because it is more easily
identified, most studies of Hib burden have focused on
detecting cases of Hib meningitis, although it is usually
acknowledged that, in the developing world, these
cases represent the tip of the Hib iceberg, most cases
being the more difficult to identify cases of Hib pneu-
monia (21).
Over the past decade, a number of studies have been
undertaken to establish the burden of Hib in Asia, most
supported by the pharmaceutical industry that was
looking to Asia as a potentially-lucrative, untapped
market for their Hib vaccines (22). However, all studies
seemed to suffer the same problems. They were con-
ducted in relatively affluent areas where the presump-
tive use of antibiotics for childhood illness was very
common. Furthermore, meningitis was often treated
empirically, without lumbar puncture. The fastidious
nature of the Hib organism meant that even when the
correct specimen was collected, the organism could
still be missed because of minor problems with media
preparation or culture technique. As a result, these
studies, developed to demonstrate the need for the vac-
cine, have instead provided evidence to support the
hypothesis that there is indeed a very low incidence of
Hib disease in Asia. As the global health community
drifts towards such a conclusion, two innovative studies
(in Indonesia and Bangladesh) have been undertaken
in which a Hib vaccine trial was conducted to deter-
mine the burden of disease. These studies were built on
the experience of trials in the Gambia and Chile where
the use of a Hib vaccine (PRP-T) produced a predictable
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reduction in the incidence of Hib meningitis (23,24). In
the case of the Gambia, the trial also demonstrated that
the vaccine had an impact on the incidence of bacterio-
logically-proven Hib pneumonia. However, the most
surprising finding from the Gambia was the 20% reduc-
tion in the incidence of radiological pneumonia in vac-
cinated children (Table 3). Similar results were obtained 
be associated with the same radiological features as was
evident in the Gambia. There was also a marked reduc-
tion in episodes of clinical meningitis in the vaccinated
group, consistent with an incidence of Hib meningitis of
over 150/100,000 children per year for children aged
less than two years. This is a rate similar to that found in
Africa and is sufficient to justify the inclusion of Hib 
Table 3. Episodes of acute respiratory infection by different categories in fully-vaccinated Gambian children
who received PRP-T Hib vaccine in infancy and controls (23)
Percentage of vaccine
ARI syndrome Hib vaccinees       Controls efficacy (95% CI)
Cough + fast breathing or lower chest wall indrawing* 526 570 7.7 (4.1,18.2)
Cough + lower chest wall indrawing† 259 286 9.4 (7.5,23.7)
Radiological pneumonia 132 170 22.4 (1.9,38.6)
Lobar pneumonia 61 72 15.3 (20.8,40.8)
Pneumonia with hypoxaemia 18 28 35.7 (20.5,66.5)
* Non-severe pneumonia, by WHO definition
† Severe pneumonia, by WHO definition
ARI=Acute respiratory infection
CI=Confidence interval
from a retrospective analysis of the Chilean data (25).
The conclusion of these studies was that, in contrast to
prospective pneumonia-aetiology studies that suggested
that 5-10% of childhood pneumonia was due to Hib, the
true figure may be closer to 20%. This finding had
important implications for the use of the vaccine. 
The first suggestion to conduct a Hib vaccine trial
with the aim of demonstrating the burden of pneumonia
came at a meeting on Hib in Asia in Bali, Indonesia, in
1997. Following that meeting, a consortium was formed
to conduct a randomized, double-blind trial of a Hib
vaccine on the Indonesian island of Lombok. In that
trial, 55,000 infants were randomized by village to
receive either Hib-DTP or DTP at 6, 10, and 14 weeks
of age (26). The primary endpoint was radiological
pneumonia and the investigators used the same defini-
tion of this endpoint developed by WHO for use in
pneumococcal vaccine trials. The trial was conducted in
a predominantly rural community with a high infant
mortality in which pneumonia is the most important
cause of mortality. It was, therefore, surprising to find
that the vaccine had essentially no impact on the inci-
dence of radiological pneumonia. There was, however,
a small reduction in the incidence of all clinical pneu-
monia, which was statistically significant due to the
large number of events detected. In addition, there was
a (non-significant) reduction in deaths due to pneumo-
nia in the vaccinated group. These findings suggest that,
in Lombok, Hib pneumonia does occur, but it may not
vaccine, even in the absence of a demonstrable effect on
pneumonia. Thus, the trial did, in fact, demonstrate a
significant burden of Hib disease, but not the manifesta-
tion that the investigators had expected.
A similar study has been completed in urban Dhaka,
Bangladesh and is awaiting analysis. Another is being
planned as a multicentre study in India.  Gradually, the
trial of Hib vaccine is becoming the standard for the
determination of Hib burden in Asia. The key unan-
swered question at this time is whether another large
trial in East Asia is needed before the Hib in Asia dilem-
ma can be resolved. In the view of this author, such a
trial will be needed before Hib vaccine is introduced in
much of Asia, particularly China.
Pneumococcal vaccine
The situation with pneumococcal vaccines promises to
be much more complex. The pneumococcus (Streptococcus
pneumoniae), like Hib, is an encapsulated bacterium in
which protective immunity is derived from antibodies
directed at the capsule. The range of conditions caused
by the pneumococcus is similar to Hib. As with Hib,
pneumonia is the most important manifestation of pneu-
mococcal disease, while meningitis is the most severe.
Indeed, pneumococcal meningitis is more severe than
Hib meningitis, and in most developing-country set-
tings, the mortality is in excess of 50% with many sur-
vivors suffering permanent neurological damage (27).
Pneumococcus is a major bacterial cause of pneumonia 
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throughout the world, but as with Hib, it is difficult to
prove pneumococcal aetiology in individual cases.
Estimates of the global burden of pneumococcal disease
range from 1 to 2 million child deaths per year with a
similar number of adult deaths. As a cause of disability
and death in humans, pneumococcus is substantially
more important than malaria and is rivaled only by
Mycobacterium tuberculosis. One might conclude,
therefore, that with such an overwhelming burden of
disease, the case for pneumococcal vaccination does not
need to be spelled out in detail. In fact, this is quite
wrong for a number of reasons.
First, the current price of new pneumococcal conju-
gate vaccines, around $ 200 per child for a 4-dose sche-
dule, breaks all records for a routine childhood vaccine.
Australia, a relatively wealthy country, recently conclud-
ed that the burden of pneumococcal disease is not suffi-
cient to justify the introduction of this vaccine, except for
the indigenous aboriginal communities who are at
extremely high risk (28) (This decision has recently been
reversed). Second, with most pneumococcal disease appea-
ring as pneumonia, estimating the burden of vaccine-pre-
ventable pneumonia is an essential, but difficult exercise.
To do this, one must first estimate the proportion of pneu-
monia cases that are pneumococcal in origin and then the
proportion that can be prevented by the vaccine. This is
extremely complex. Definitively identifying a case of pneu-
monia as pneumococcal in origin requires culture of pneu-
mococcus from blood or lung fluid, and as this is not pos-
sible in many cases, prospective studies are always left
speculating about how many cases they missed. The pro-
portion of cases in a series that prove to be pneumococcal
depends on the point in the healthcare chain where cases
are recruited. Studies conducted at community level typi-
cally yield small numbers of pneumococci (9), while 
those at hospital level, recruiting more severe cases, see
more pneumococcal cases (29). Then there are at least
90 serotypes of pneumococcus that can cause disease in
humans (30), although, in most settings, most cases are
caused by the serotypes included in the current pneumo-
coccal conjugate vaccine. Some serotypes appear to be
more likely to cause bacteraemic disease, while some
seem to have a predeliction to cause more severe dis-
ease, particularly meningitis (11). It is possible that
some serotypes are more likely to cause non-bacteraemic
pneumonia, but this is very difficult to determine.
These factors and the need to consider other manifes-
tations of pneumococcal disease, such as otitis media
and febrile bacteraemia, may lead one to the conclusion
that the only way to reliably estimate the burden of vac-
cine-preventable pneumococcal disease is within a vac-
cine trial. This may be true, and current phase III pneu-
mococcal vaccine trials underway in the Gambia and the
Philippines contain elements designed to estimate com-
ponents of the overall burden of pneumococcal disease.
This can be achieved by ascertaining, within a defined
population, the number of cases of each pneumococcal
syndrome that are prevented. These syndromes range
from relatively mild conditions, such as otitis media, to
death. A possible framework for assessing the burden of
pneumococcal disease from a vaccine trial is presented
in Table 4. This would enable the presentation of, for
each 1,000 children immunized, the number of cases of
each disease manifestation prevented, the total cost sav-
ings, and the number of deaths prevented. For some
parameters, the estimates will be crude, and case-fatality
rates will need to take account of the likelihood that a
child with the condition will not be treated, or will
receive inadequate care, in the country concerned. 
Table 4. A potential framework for assessing burden of pneumococcal disease from a vaccine trial
Cases                     Cases Cost Cost                                  Deaths
Disease          prevented in prevented per    per case         saving per Case- prevented per
manifestation vaccines vs 1,000 children   of disease    1,000 children fatality rate    1,000 children
controls immunized                           immunized immunized
Otitis media a b $c $b.c d b.d
(a.1000/trial size)
Febrile 
bacteraemia
Radiological 
pneumonia
Other ARIs
Meningitis
ARIs=Acute respiratory infections
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Impact on overall mortality has always been seen as the
most compelling evidence a trial can produce for the
use of a vaccine claiming to improve child survival.
Only the Gambian trial has been designed with this
endpoint in mind, yet as a result of decisions made in
the United States, based on perceptions of the ethical
acceptability of the trial, that trial has been stopped
with only half the required number of subjects recruited,
so it no longer has the power to provide this important
information. Data from the Philippines may be diffi-
cult to interpret as the efficacy of the vaccine used in
that trial (11-valent Aventis pneumococcal conjugate
vaccine) is unknown, and no other trials are planned
with that vaccine.  If the trial does show an impact on
incidence of pneumonia, it can be assumed that the
observed impact represents the vaccine-preventable
fraction of pneumonia, but if the results are negative, it
will not be known whether the vaccine is ineffective,
or the fraction of pneumonia due to pneumococci in
that community is very small. Despite the problems,
these trials have the potential to provide substantial
information on the burden of pneumococcal disease in
those communities yet even these large, expensive
studies may yield misleading results.
It has now been shown in a number of studies that
children vaccinated with the pneumococcal conjugate
vaccine are less likely to be nasopharyngeal carriers of
the pneumococcal serotypes they have been vaccinated
against, but more likely to carry other serotypes. This
phenomenon is referred to as 'serotype replacement'
(31). A key question surrounding this whole pneumo-
coccal vaccination strategy is whether serotype replace-
ment will also occur in disease, with vaccination lead-
ing to an increase in disease due to non-vaccine
serotypes. This has been shown to occur with otitis
media, and the U.S. data suggest that it may be occur-
ring there with invasive disease (32), although the
numbers are small (as so little childhood disease in the
United States is due to serotypes not in the vaccine). It
is likely that the same phenomenon will occur in pneu-
monia cases, but if the 'new' serotypes are less likely to
lead to bacteraemia, this may be extremely difficult to
detect. It may, however, offset the total number of
pneumonia cases prevented by the vaccine, and the
lower-than-expected efficacy observed in South
Africa, and the U.S. Navajo Indian studies suggest that
this may have happened in those trial settings. With a
higher proportion of the population vaccinated, the
effect will be accentuated by herd effects that will
then increase with time as more children in the commu-
nity are vaccinated. Thus, when a whole community is
vaccinated, the burden of vaccine-preventable pneumo-
nia may move towards zero, despite the existence of a
substantial pneumococcal burden and an effective vac-
cine. Nevertheless, from a public-health standpoint, it is
the effectiveness of a vaccine when it is applied to a com-
munity that matters, not the efficacy at individual level.
Bridging from vaccine trials
As few countries have the opportunity to conduct a
large vaccine trial in their own communities, and the
burden of vaccine-preventable diseases is likely to
vary considerably between communities, it is neces-
sary to develop mechanisms to bridge epidemiological
information from smaller field studies so that conclu-
sions about burden of disease can be drawn. At its sim-
plest level, this will mean prospective studies of the
incidence of the main endpoint(s) measured in the con-
text of the phase III vaccine trials. Pneumococcal vac-
cines present the most complex problem for these
bridging studies. Measurement of the incidence in a
community of pneumococcal meningitis, radiological
pneumonia and otitis media would allow data such as
that collected in Table 4 to be used for calculating the
burden of vaccine-preventable diseases in that setting.
It is probably sufficient to take a key indicator, such as
the incidence of radiological pneumonia and to use this
to establish a multiplier that will relate the burden of
disease in the setting under investigation to that found
at the vaccine trial site. Thus, population-based studies
of radiological pneumonia, using identical definitions
to those used in the vaccine trials, will form the main
bridge for pneumococcal vaccines. With rotavirus vac-
cines, a convenient bridging parameter is the propor-
tion of children admitted with diarrhoea who are
infected with rotavirus. The Global Alliance for
Vaccines and Immunization has now taken responsibi-
lity for this work, so funding should soon be available
for these studies in both pneumococcal and rotavirus
fields (www.vaccinealliance.org).
Non-specific effects of vaccines
Recent work from West Africa has provided evidence
that certain vaccines have an impact on mortality that
is beyond that which can be accounted for by preven-
tion of a specific disease. The authors of the work, pub-
lished in December 2000, suggest that non-specific
stimulation of the immune system, following measles 
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or BCG immunization, results in a decreased risk of
mortality from all causes (33). In contrast, their find-
ings suggest that administration of non-live vaccines,
particularly DTP and hepatitis B, results in an
increased risk of mortality, presumably due to similar
mechanisms. Confronted with this troubling informa-
tion, WHO's Global Advisory Committee on Vaccine
Safety created a special sub-committee to resolve this
issue. They commissioned a series of retrospective
analyses of old datasets that may be able to address
these issues. Initial reports from the group suggest that
effects similar to those described in Guinea Bissau
have not been found at the other sites, but the studies
have not yet been made public, and expert analysis and
interpretation of the results is ongoing (34). Meanwhile,
in the immunology literature, there is a growing body
of evidence to suggest that T-cell-mediated immunity
may not be as specific as has been believed (35).
Heterologous T-cell immunity may mean that prior
antigenic experience could have positive or negative
effects on the response of an individual to an apparently-
unrelated infection. These findings provide a potential
immunological basis for the non-specific vaccine
effects described in Guinea Bissau. If this is true in
humans, even a small effect could potentially invali-
date the vaccine-trial approach to burden of disease. A
small effect on mortality could signify a larger, non-
specific effect on the incidence or severity of infec-
tious disease. The vaccine-trial approach to disease-
burden estimation relies on the assumption that the
vaccine only affects disease caused by the organism
against which it is directed. If the vaccine has preven-
tative effects beyond that organism, the burden of disease
attributed to that organism will be erroneously large.
If, on the other hand, the vaccine has negative effects
resulting in more illness in vaccinees, the calculated
burden of disease will be erroneously small.  
CONCLUSION
As life-saving childhood vaccines become more
expensive, governments around the world face agoni-
zing decisions about the incorporation of new vaccines
into the routine schedules for their children. Central to
this decision-making is an understanding of the bene-
fits that will accrue if the vaccine is introduced. This,
in turn, requires an understanding of the burden of disease
due to the organism against which the vaccine is directed.
The most useful presentation of disease-burden infor-
mation is the burden of vaccine-preventable diseases, 
which is most accurately and practically measured in a
vaccine trial. As vaccine trials can only be conducted
in a few settings, it is necessary to conduct a series of
bridging studies to provide disease-burden estimates at
country level that can be used as the basis for economic
analyses to support the introduction of vaccine.
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